Catalyst Dossier · compiled by CeliA 🧫

Organon & Co. (OGN)

Pharmaceutical Preparations · market cap $3.5B · as of 2026-06-29

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-04

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Organon & Co. (OGN) is a specialty pharmaceutical company spun off from Merck, focused on reproductive health, contraception, psychiatry, hormone replacement therapy, and anesthesia, with roughly $6.2B in annual revenue but carrying $7.5B in net debt against a $3.5B market cap. The pipeline is heavily composed of late-stage generics, biosimilars, and line extensions of established molecules — alendronate, simvastatin, ezetimibe, montelukast, desloratadine — rather than novel first-in-class assets. The next near-term event is an August 4, 2026 earnings release rated 5/10 on expected impact.

The catalyst path

2026-08-04Earningsimp 5/10

Pipeline

Asset	Phase	Indication
MK0217, alendronate sodium / Duration of Treatment : 2 Years	Phase 3	Osteoporosis, Postmenopausal
simvastatin	Phase 3	Hypercholesterolemia
montelukast sodium	Phase 3	Seasonal Allergic Rhinitis
ezetimibe (+) simvastatin	Phase 3	Hyperlipidemia
Corifollitropin alfa	Phase 3	In Vitro Fertilization
Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg	Phase 2	Asthma
atorvastatin	Phase 3	Hypercholesterolemia
Tibolone 2.5 mg	Phase 3	Postmenopausal Women
Desloratadine 2.5 mg	Phase 2	Post-nasal Drip
MK0663, Etoricoxib / Duration of Treatment : 12 Weeks	Phase 3	Recurrent Low Back Pain
A-Phase: tirofiban; Z-Phase simvastatin	Phase 3	Acute Coronary Syndrome
MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet	Phase 3	Osteoporosis
Radiopaque Implanon	Phase 3	Contraception
MK-0653, ezetimibe	Phase 3	Hypercholesterolaemia
ezetimibe 10 mg	Phase 3	Hypercholesterolemia
losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])	Phase 3	Hypertension
NOMAC-E2	Phase 3	Contraception
olanzapine	Phase 3	Schizophrenia
MK0653, ezetimibe	Phase 3	Lipid Metabolism, Inborn Errors
Desloratadine (Clarinex)	Phase 3	Allergic Rhinitis

Price & technical context

3-month

+120.7%

6-month

+90.0%

12-month

+34.8%

52-wk range

$5.70–$13.55

vs 50-day MA

+2.9%

vs 200-day MA

+46.6%

Realized vol

66.7%

Max drawdown

-75.2%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for OGN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.